Teva Pharmaceutical Industries stock gains on NYSE listing milestone

Teva Pharmaceutical Industries Ltd. stock (ISIN US88162G1031) closed at USD 38.98 on the New York Stock Exchange on September 18, 2026, up 36.25 percent year to date and 5.35 percent over the past five sessions, while still below its recent 52-week high.Zonebourse On September 14, 2026, Teva marked a strategic milestone by beginning direct trading of its ordinary shares on the NYSE, replacing its former American Depositary Shares program and aligning its listing with its pivot-to-growth strategy.Globe Newswire For investors, the combination of a strong share performance and a simplified NYSE listing sets the stage for Teva’s next operational and financial checkpoints.

NYSE ordinary-share listing supports Teva’s growth pivot

According to Globe Newswire on September 14, 2026, Teva announced that its ordinary shares began trading directly on the NYSE that day under the existing TEVA ticker, completing the planned transition away from its American Depositary Shares program. The company highlighted this move as a milestone in its pivot-to-growth strategy, which seeks to leverage its global biopharmaceutical portfolio, including generics and specialty medicines, under a more streamlined equity structure. Teva’s shares continue to trade under the TEVA symbol on both the NYSE and the Tel Aviv Stock Exchange, reinforcing its dual-market presence while making the U.S. listing more straightforward for international investors.

The direct listing of ordinary shares on the NYSE can improve visibility and liquidity, particularly for institutional investors that prefer ordinary shares over depositary receipts. In practice, this structure may facilitate index inclusion decisions and simplify corporate actions, even if the immediate financial impact is limited. From an investor’s perspective, the milestone signals management’s focus on capital-market alignment as part of the broader growth strategy, complementing operational initiatives such as pipeline development and cost discipline. The move also comes at a time when the share price has delivered a double-digit performance year to date, which strengthens the narrative that Teva’s strategic repositioning is gaining traction.

New data in schizophrenia and movement-disorder portfolio

Beyond the listing change, Teva has recently highlighted new clinical and real-world data in key central nervous system segments. On September 18, 2026, Teva presented post hoc data on its long-acting olanzapine injection candidate TEV-749, showing high stabilization rates and long-term efficacy with a once-monthly subcutaneous administration for adults with schizophrenia, according to Zonebourse. Such data underpin Teva’s specialty portfolio strategy by supporting potential future regulatory submissions and commercialization efforts in long-acting antipsychotic treatments.

In parallel, Teva underscored new real-world evidence for its long-acting injectable risperidone product UZEDY in schizophrenia. According to a press release dated September 18, 2026, Teva reported that UZEDY outperformed other long-acting injectables in keeping patients on treatment, while reducing emergency care and healthcare costs, based on real-world data analysis.Via Ritzau These results support Teva’s emphasis on long-acting injectable solutions that aim to improve adherence and reduce the burden on healthcare systems, and they provide a clinical backdrop for the company’s growth ambitions.

Stock performance and investor perspective

Market data indicate that Teva’s share price of USD 38.98 on the NYSE at the close on September 18, 2026, represents a gain of 36.25 percent since the beginning of 2026 and 5.35 percent over the prior five days, while the daily move that session was a modest decline of 0.54 percent.Zonebourse A separate market overview lists Teva’s market capitalization at about USD 45.46 billion as of September 18, 2026, placing the company among the larger global players in the drug manufacturers specialty and generic segment.Yahoo Finance For investors, the combination of strong year-to-date performance and recent operational news in schizophrenia and movement-disorder treatments forms a coherent narrative of a company seeking to translate clinical data and strategic listing changes into sustained equity-market support.

While the latest press releases focus on clinical and real-world outcomes rather than new financial guidance, they underscore Teva’s effort to differentiate its portfolio in central nervous system disorders and to back its growth story with data in areas such as tardive dyskinesia and schizophrenia. As Teva continues its pivot-to-growth strategy, the next checkpoints for investors will be the company’s upcoming financial disclosures and potential regulatory milestones for pipeline assets like TEV-749 and the continued performance of products such as UZEDY. In this context, the recent NYSE ordinary-share listing and the share-price gains since the start of the year provide a market backdrop for assessing whether Teva can sustain its momentum.

Teva stock price level and market data

Teva Pharmaceutical Industries stock last closed at USD 38.98 on the NYSE on September 18, 2026, representing a daily decline of 0.54 percent but leaving the shares near their recent high for the year and substantially above their level at the start of 2026.Zonebourse With a market capitalization of roughly USD 45.46 billion as of the same date,Yahoo Finance the company occupies a prominent position in the global generics and specialty pharmaceuticals sector, and its NYSE-traded ordinary shares give international investors a direct avenue to participate in its strategic and clinical developments.

More news and analyses on Teva Pharmaceutical Industries stock